Anemia aplástica: diagnóstico, fisiopatologia imune e abordagens terapêuticas.
Revista ft · 10.06.2026 · 30 (159) · 01-17
DOI: 10.69849/gg5nfp21 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista ft, online erschienen am 10.06.2026. Verfasst von Ricardo Melo Brandão und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Aplastic anemia is a rare, but potentially fatal, bone marrow failure syndrome characterized by hypocellular marrow and peripheral pancytopenia. The acquired variant is primarily immune-mediated, involving cytotoxic T lymphocytes, inflammatory cytokines, and functional destruction of hematopoietic stem cells.
Objective
To systematically analyze the epidemiological, pathophysiological, diagnostic, prognostic, and mechanical factors related to aplastic anemia, with reference to immune pathophysiology, hematopoietic stem cell transplantation, immunosuppression, eltrombopag, relapse, clonal evolution, and emerging therapy.
Methods
Searches were conducted throughout PubMed/MEDLINE, SciELO, ScienceDirect, and Portal CAPES from 2014 to 2024, using DeCS/MeSH descriptors in combination with Boolean operators. Workflow: Use of PICOS criteria, independent screening by two reviewers, assessment of risk of bias based on study design, and appropriate descriptive statistical synthesis.
Results
142 records were identified. After removing duplicates, title/abstract screening, full-text evaluation, and application of eligibility criteria, 37 studies were included in the qualitative synthesis. The findings reinforce that diagnosis needs to be based on a combined approach including blood count and reticulocytes, bone marrow aspirate and biopsy, and exclusion of secondary causes based on disease severity; the choice of TNF treatment is determined by age, severity, donor availability, comorbidities, and risk of complications.
Conclusion
Modern management of aplastic anemia should be individualized and based on early diagnosis, risk stratification (including the use of prognostic models), transfusion support, anti-infective prophylaxis (and treatment when indicated), transplantation as appropriate, and immunosuppression with the incorporation of thrombopoietin receptor agonists.
Zitieren
APA
Brandão, R. M., Silva, L. H. F., & Jatobá, P. V. M. G. (2026). Anemia aplástica: diagnóstico, fisiopatologia imune e abordagens terapêuticas. Revista ft, 30(159), 01-17. https://doi.org/10.69849/gg5nfp21
Vancouver
Brandão RM, Silva LHF, Jatobá PVMG. Anemia aplástica: diagnóstico, fisiopatologia imune e abordagens terapêuticas. Revista ft. 2026;30(159):01-17. doi:10.69849/gg5nfp21
BibTeX
@article{Brando2026,
author = {Brandão, Ricardo Melo and Silva, Luís Henrique Ferreira and Jatobá, Priscilla Vicente Moura Galvão},
title = {Anemia aplástica: diagnóstico, fisiopatologia imune e abordagens terapêuticas},
journal = {Revista ft},
year = {2026},
volume = {30},
number = {159},
pages = {01--17},
doi = {10.69849/gg5nfp21}
}
EUVIMED